Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Brett A. Carlson"'
Autor:
Daniel J. Laverty, Shiv K. Gupta, Gary A. Bradshaw, Alexander S. Hunter, Brett L. Carlson, Nery Matias Calmo, Jiajia Chen, Shulan Tian, Jann N. Sarkaria, Zachary D. Nagel
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-22 (2024)
Abstract Determining the balance between DNA double strand break repair (DSBR) pathways is essential for understanding treatment response in cancer. We report a method for simultaneously measuring non-homologous end joining (NHEJ), homologous recombi
Externí odkaz:
https://doaj.org/article/7479bc151d014f1284e20c0dda5db9c3
Autor:
Melissa Adkins-Hempel, Sandra J. Japuntich, Michelle Chrastek, Shira Dunsiger, Christopher E. Breault, Woubeshet Ayenew, Susan A. Everson-Rose, Prabhjot S. Nijjar, Beth C. Bock, Wen-Chih Wu, Michael D. Miedema, Brett M. Carlson, Andrew M. Busch
Publikováno v:
Addiction Science & Clinical Practice, Vol 18, Iss 1, Pp 1-16 (2023)
Abstract Background Approximately 400,000 people who smoke cigarettes survive Acute Coronary Syndrome (ACS; unstable angina, ST and non-ST elevation myocardial infarction) each year in the US. Continued smoking following ACS is an independent predict
Externí odkaz:
https://doaj.org/article/9e3c7f9c51de4221a7baabfaf6f7d1ca
Autor:
Kshama Gupta, Ivan Vuckovic, Song Zhang, Yuning Xiong, Brett L. Carlson, Joshua Jacobs, Ian Olson, Xuan-Mai Petterson, Slobodan I. Macura, Jann Sarkaria, Terry C. Burns
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Glioblastoma (GBM) is uniformly fatal with a 1-year median survival, despite best available treatment, including radiotherapy (RT). Impacts of prior RT on tumor recurrence are poorly understood but may increase tumor aggressiveness. Metabolic changes
Externí odkaz:
https://doaj.org/article/7930d328fe63410ca2add16c7b58b4d7
Autor:
Elizabeth C. Randall, Kristina B. Emdal, Janice K. Laramy, Minjee Kim, Alison Roos, David Calligaris, Michael S. Regan, Shiv K. Gupta, Ann C. Mladek, Brett L. Carlson, Aaron J. Johnson, Fa-Ke Lu, X. Sunney Xie, Brian A. Joughin, Raven J. Reddy, Sen Peng, Walid M. Abdelmoula, Pamela R. Jackson, Aarti Kolluri, Katherine A. Kellersberger, Jeffrey N. Agar, Douglas A. Lauffenburger, Kristin R. Swanson, Nhan L. Tran, William F. Elmquist, Forest M. White, Jann N. Sarkaria, Nathalie Y. R. Agar
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Despite major drug discovery efforts, the therapeutic options for glioblastoma (GBM) remain inadequate. Here they analyze patient-derived xenograft model of GBM to quantitatively map distribution and cellular response to the EGFR inhibitor erlotinib,
Externí odkaz:
https://doaj.org/article/17219987055045cbbd74e20d4356a523
Autor:
Jason E Conage-Pough, Sylwia A Stopka, Ju-Hee Oh, Ann C Mladek, Danielle M Burgenske, Michael S Regan, Gerard Baquer, Paul A Decker, Brett L Carlson, Katrina K Bakken, Jinqiang Zhang, Lily Liu, Claire Sun, Zhihua Mu, Wei Zhong, Nhan L Tran, William F Elmquist, Nathalie Y R Agar, Jann N Sarkaria, Forest M White
Publikováno v:
Neuro-Oncology Advances.
Background Although the epidermal growth factor receptor (EGFR) is a frequent oncogenic driver in glioblastoma (GBM), efforts to therapeutically target this protein have been largely unsuccessful. The present pre-clinical study evaluated the novel EG
Autor:
Jann N. Sarkaria, William F. Elmquist, Andrew A. Protter, Ying Feng, Yuqiao Shen, Gaspar J. Kitange, Paul A. Decker, Mark A. Schroeder, Ann C. Mladek, Katrina K. Bakken, Brett L. Carlson, Karen E. Parrish, Ryo Kawashima, Kenneth Chang, Shiv K. Gupta, Sani H. Kizilbash
Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models. This study eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::610fead5e240273df4c9b17631c87d5c
https://doi.org/10.1158/1535-7163.c.6538018.v1
https://doi.org/10.1158/1535-7163.c.6538018.v1
Autor:
Jann N. Sarkaria, William F. Elmquist, Andrew A. Protter, Ying Feng, Yuqiao Shen, Gaspar J. Kitange, Paul A. Decker, Mark A. Schroeder, Ann C. Mladek, Katrina K. Bakken, Brett L. Carlson, Karen E. Parrish, Ryo Kawashima, Kenneth Chang, Shiv K. Gupta, Sani H. Kizilbash
Evaluation of sensitizing effects of TAL in GBM cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37be1fdfda968d46ee4b4d22cb01bc32
https://doi.org/10.1158/1535-7163.22505305.v1
https://doi.org/10.1158/1535-7163.22505305.v1
Autor:
Jann N. Sarkaria, William F. Elmquist, Nicola J. Curtin, Nathalie Y.R. Agar, Alan V. Boddy, Julieann Sludden, Mark A. Schroeder, Brett L. Carlson, Rajendar K. Mittapalli, Sani Kizilbash, David Calligaris, James Murray, Ling Cen, Karen E. Parrish
Supplemental Figure 1. MALDI FTICR mass spectra selected from a pixel with maximum intensity in the MS images of liver (A) and flank tumor (B) sections showing the two first isotopes of rucaparib (peaks labelled 1 and 2, respectively). (C) MALDI FTIC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1129c787b2292e6df7e3ef3694a32e7c
https://doi.org/10.1158/1535-7163.22503525.v1
https://doi.org/10.1158/1535-7163.22503525.v1
Autor:
Jann N. Sarkaria, William F. Elmquist, Andrew A. Protter, Ying Feng, Yuqiao Shen, Gaspar J. Kitange, Paul A. Decker, Mark A. Schroeder, Ann C. Mladek, Katrina K. Bakken, Brett L. Carlson, Karen E. Parrish, Ryo Kawashima, Kenneth Chang, Shiv K. Gupta, Sani H. Kizilbash
Supplementary methods and Captions to the Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c1dd961369700b863b7c74aa06bee26
https://doi.org/10.1158/1535-7163.22505281.v1
https://doi.org/10.1158/1535-7163.22505281.v1
Autor:
Jann N. Sarkaria, William F. Elmquist, Paul A. Decker, Mark A. Schroeder, Ann C. Mladek, Katrina K. Bakken, Brett L. Carlson, Gautham Gampa, Minjee Kim, Janice K. Laramy, Karen E. Parrish, Shiv K. Gupta, Sani H. Kizilbash
Tesevatinib is a potent oral brain penetrant EGFR inhibitor currently being evaluated for glioblastoma therapy. Tesevatinib distribution was assessed in wild-type (WT) and Mdr1a/b(-/-)Bcrp(-/-) triple knockout (TKO) FVB mice after dosing orally or vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206b43b8da91279e8c66cb03985a2c44
https://doi.org/10.1158/1535-7163.c.6543372
https://doi.org/10.1158/1535-7163.c.6543372